We wrote about Stericycle (SRCL) last month and stated that we believed there still was significant upside in the stock. We believe that once the business transformation that the company has been undergoing really takes effect, the firm should be able to take advantage of plenty of up-selling opportunities to existing clients.
We have long since stated that Stericycle has all the hallmarks of being a strong value play. Earnings have temporarily come under pressure for multiple reasons and the company has tried to pivot, which only increased costs. We maintain though that